| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.04. | Apollomics GAAP EPS of -$7.57, revenue of $8.5M | 1 | Seeking Alpha | ||
| 27.04. | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.04. | Apollomics Inc. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| APOLLOMICS Aktie jetzt für 0€ handeln | |||||
| 01.04. | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.04. | Apollomics Inc. Announces $2.0 Million Bridge Financing | 1 | GlobeNewswire (USA) | ||
| 02.02. | Apollomics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 23.12.25 | Apollomics H1 Loss Narrows | 2 | RTTNews | ||
| 22.12.25 | Apollomics GAAP EPS of -$11.37 | 3 | Seeking Alpha | ||
| 22.12.25 | Apollomics Inc.: Apollomics Reports First Half 2025 Financial Results | 176 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology... ► Artikel lesen | |
| 22.12.25 | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.12.25 | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.11.25 | Apollomics Inc.: Apollomics Announces Settlement of Cayman Litigation | 184 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (Nasdaq: APLM) announced today entering into a settlement agreement (the "Settlement Agreement"... ► Artikel lesen | |
| 15.10.25 | Apollomics Inc.: Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation | 244 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharmaceutical company developing multiple... ► Artikel lesen | |
| 14.10.25 | Apollomics Inc.: Apollomics, Inc. Company Operational Continuity Update | 214 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,30 | +0,77 % | Tagesvorschau 15. Mai: Biontech-HV, BVB-Quartal, US-Industriedaten - das bringt der Freitag | Die turbulente Bilanzwoche klingt aus - doch der Freitag hält für Anleger noch einige spannende Termine bereit.Zum Wochenausklang dünnt der Terminkalender zwar aus, gewinnt aber spürbar an Schärfe.... ► Artikel lesen | |
| EVOTEC | 5,080 | +3,67 % | KAUFKURSE bei Renk und Desert Gold! SCHOCK bei der Evotec Aktie! | Während der Goldpreis schwächelt, befindet sich die Aktie von Desert Gold in einem sauberen Aufwärtstrend. Und geht es nach Analysten, ist eine Vervielfachung möglich. Denn Desert Gold wird in wenigen... ► Artikel lesen | |
| AMGEN | 290,00 | +1,68 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| NANOREPRO | 1,650 | +0,61 % | NanoRepro: Mit Elan gestartet | "Wir sind auf einem guten Weg", sagt Lisa Jüngst, CEO von NanoRepro, am Ende ihrer Präsentation auf der Frühjahrskonferenz in Frankfurt. Die Aufgabenstellung könnte dabei ambitionierter kaum sein. Immerhin... ► Artikel lesen | |
| BIOXXMED | 0,800 | 0,00 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,400 | +4,14 % | Could Viking Therapeutics Be the Next Eli Lilly? | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,289 | +4,71 % | Defence Therapeutics Inc.: Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,396 | -1,74 % | Patentschutz bis 2040: NurExone stärkt seine Exosomen-Produktionstechnologie | ||
| ABIVAX | 105,20 | +3,85 % | Abivax S.A. - 6-K, Report of foreign issuer | ||
| IBIO | 1,628 | +10,37 % | iBio, Inc.: iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors | SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,930 | +2,20 % | RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | 2025 was a year of tenacity, strategic transactions and building traction for RedHill
Talicia® business transformed:
Formation of Talicia Holdings Inc. (THI) and... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 60,44 | -8,87 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events | Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
BofA Securities 2026 Healthcare Conference May 12-14, 2026
Type:... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,104 | +2,99 % | Voyager Therapeutics, Inc.: Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 | - VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON... ► Artikel lesen | |
| CELLECTIS | 3,070 | -0,58 % | Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026 |